Table 1.

Bone marrow biopsy, blood test results, and clinical assessment from diagnosis, remission and relapse

Variable	Diagnosis	21 days post induction chemotherapy	23 days post salvage chemotherapy	2 months into ascorbate treatment	Relapse	Relapse post induction chemotherapy	Relapse	Relapse	Normal range
Timeline (months post diagnosis)	0	1	2	4	34	36	38	41
Bone marrow blast count (% of nucleated cells)	75	30–80	57–65	0	76	>90	61–85	96	<5
Hemoglobin (g/dL)	9.8	11.2	9.7	13.3	11.0	9.6	12.1	9.9	13.0–17.5
White Cell Count (×109/L)	1.53	1.08	0.26	3.2	1.6	1.6	2.1	3.6	4.0–11.0
Neutrophils (×109/L)	0.14	0.46	0.0	1.8	0.4	0.29	1.3	0.36	1.9–7.5
Circulating blasts (×109/L)	0.2	0.0	0.0	0.0	Occasional	0.04	0.0	2.4	0
Platelets (×109/L)	73	228	16	83	89	89	116	36	150–400
Molecular Pathologya	NPM1+ve	NDb	ND	NPM1–ve	ND	ND	ND	ND
Clinical assessment	Acute Myeloid Leukemia	Refractory to chemotherapy	Refractory to chemotherapy	Clinical remission	Relapse	Refractory to chemotherapy	Persistent AML	Persistent AML

^aMolecular Pathology testing involved PCR and Sanger sequencing in order to detect mutations in NPM1, CEPBA and FLT3

^bND, investigation was not done at this time point